5 Unknown Biotech Stocks That Can Explode in 2022

2. OptiNose, Inc. (NASDAQ:OPTN)

Number of Hedge Fund Holders: 10  

OptiNose, Inc. (NASDAQ:OPTN) is a biopharma firm focusing on the development of drugs for disorders related to the ear, nose, and throat. On June 13, the share price of the firm jumped over 36% after the firm announced Phase 3 data from the trial of a drug named Xhance, a treatment for chronic sinusitis patients. The firm said the data indicated that the drug had a “safety and tolerability profile consistent with its current labeling”. The results of the study are yet to undergo a peer review. 

On June 13, Piper Sandler analyst David Amsellem reiterated an Overweight rating on OptiNose, Inc. (NASDAQ:OPTN) stock with a price target of $4, noting that the firm had a clear path to label expansion with regards to new drug Xhance. 

At the end of the first quarter of 2022, 10 hedge funds in the database of Insider Monkey held stakes worth $23 million in OptiNose, Inc. (NASDAQ:OPTN), compared to 8 in the preceding quarter worth $10 million. 

Among the hedge funds being tracked by Insider Monkey, Oregon-based investment firm Stonepine Capital is the only shareholder in OptiNose, Inc. (NASDAQ:OPTN) with 2.9 million shares worth $7.2 million.